IBM Micromedex® Compendium

Through the process established by the Centers for Medicare and Medicaid Services (CMS), IBM® Micromedex® DRUGDEX® is recognized by CMS as a compendium for the determination of payment for medically-accepted off-label uses for anti-cancer regimens. Effective January 1, 2010, new requirements were implemented that include a provision for providing transparency of processes used to evaluate therapies and to identify potential conflicts of interest. Specifically, publishers of compendia must now make the following information available via their public websites:

  • Criteria used to evaluate the request (therapy)
  • Disclosure of evidence considered
  • Meeting minutes and records of votes for disposition of the request (therapy)
  • Names of individuals who have substantively participated in the development of the compendia recommendations and disclosure of any potential conflicts of interest

To meet these requirements, documents detailing this information for each drug/off-label use pair published on or after January 1, 2010 are posted below. Information is organized by drug name, with the document title indicating the off-label use. Further transparency regarding Micromedex Off-Label processes can be found in the Micromedex Compendia Uses Policy.

DrugDex Off-Label Use Tracking

Abemaciclib
Abiraterone Acetate
Acitretin
Ado-Trastuzumab Emtansine
Afatinib Dimaleate
Alemtuzumab
Anastrozole
Antithymocyte Globulin Equine
Antithymocyte Globulin Rabbit
Apixaban
Arsenic Trioxide
Asparaginase Escherichia Coli
Atezolizumab
Axitinib
Bendamustine
Bevacizumab
Bortezomib
Brentuximab vedotin
Cabozantinib Malate
Capecitabine
Carboplatin
Carfilzomib
Celecoxib
Cetuximab
Cisplatin
Cladribine
Cyclophosphamide
Dabrafenib Mesylate
Dalteparin
Daratumumab
Dasatinib
Defibrotide Sodium
Dexmethylphenidate
Docetaxel
Doxorubicin Hydrochloride Liposome
Dutasteride
Edoxaban
Eltrombopag Olamine
Enoxaparin Sodium
Eribulin Mesylate
Everolimus
Exemestane
Febuxostat
Fluorouracil
Fosaprepitant Dimeglumine
Fulvestrant
Gefitinib
Gemcitabine Hydrochloride
Goserelin acetate
Hydroxyurea
Imatinib Mesylate
Inotuzumab
Irinotecan Hydrochloride
Iron Dextran
Isotretinoin
Ixazomib
Ketamine Hydrochloride
Lenalidomide
Melphalan Hydrochloride
Methylphenidate Hydrochloride
Modafinil
Naldemedine
Nilotinib
Nilotinib Hydrochloride
Nintedanib
Nivolumab
Olanzapine
Olaparib
Oxaliplatin
Paclitaxel protein-bound
Panitumumab
Panobinostat
Pasireotide
Pazopanib Hydrochloride
Pegaspargase
Pegfilgrastim
Peginterferon alfa-2a
Peginterferon alfa-2b
Pembrolizumab
Pemetrexed
Pertuzumab
Pomalidomide
Ponatinib Hydrochloride
Porfimer Sodium
Prochlorperazine
Pyridoxine
Ramucirumab
Regorafenib
Risedronate Sodium
Rituximab
Rivaroxaban
Romiplostim
Ruxolitinib Phosphate
Sodium Ferric Gluconate
Sorafenib Tosylate
Sunitinib Malate
Tamoxifen
Thalidomide
Trabectedin
Trastuzumab
Toremifene citrate
Triptorelin pamoate
Vandetanib
Vemurafenib
Vinorelbine
Zoledronic acid